Literature DB >> 2135383

Subretinal neovascularization following multiple evanescent white-dot syndrome.

G J Wyhinny, J L Jackson, L M Jampol, N C Caro.   

Abstract

Mesh:

Year:  1990        PMID: 2135383     DOI: 10.1001/archopht.1990.01070120030013

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


× No keyword cloud information.
  6 in total

1.  Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in an elderly UK population-the Bridlington eye assessment project (BEAP): a cross-sectional study (2002-2006).

Authors:  Craig Wilde; Ali Poostchi; Rajnikant L Mehta; Jonathan G Hillman; Hamish K MacNab; Marco Messina; Gaspare Monaco; Stephen A Vernon; Winfried M Amoaku
Journal:  Eye (Lond)       Date:  2018-10-12       Impact factor: 3.775

2.  Fundal white dots: the spectrum of a similar pathological process.

Authors:  D Ben Ezra; J V Forrester
Journal:  Br J Ophthalmol       Date:  1995-09       Impact factor: 4.638

3.  Idiopathic choroidal neovascularisation as the inaugural sign of multiple evanescent white dot syndrome.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Diagnosis and Treatment of Primary Inflammatory Choriocapillaropathies (PICCPs): A Comprehensive Overview.

Authors:  Ioannis Papasavvas; Carl P Herbort
Journal:  Medicina (Kaunas)       Date:  2022-01-21       Impact factor: 2.430

Review 5.  Multiple evanescent white dot syndrome (MEWDS): update on practical appraisal, diagnosis and clinicopathology; a review and an alternative comprehensive perspective.

Authors:  Ioannis Papasavvas; Alessandro Mantovani; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-12-18

6.  Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots.

Authors:  Alfredo Pece; Davide Allegrini; Stelios Kontadakis; Giuseppe Querques; Luca Rossetti
Journal:  BMC Ophthalmol       Date:  2016-07-26       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.